Halozyme Therapeutics HALO EBIT

EBIT at other companies

West Pharmaceutical ServicesWST

$179.1M+16.5%

AMP

Amphastar PharmaceuticalsAMPH

$39.73M-5.8%

AptarGroupATR

$107.5M-5.2%

Opko HealthOPK

-$6.97M+88.4%

Amneal Pharmaceuticals, Inc.AMRX

$129.77M+16.5%

Aquestive Therapeutics, Inc.AQST

-$4.2M+78.3%

FAQ

What is Halozyme Therapeutics's EBIT?

Halozyme Therapeutics (HALO) reported EBIT of $287.65M in Q2 2026.

How has Halozyme Therapeutics's EBIT changed year-over-year?

Halozyme Therapeutics's EBIT increased by 42.1% year-over-year, from $202.44M to $287.65M.

What is the long-term trend for Halozyme Therapeutics's EBIT?

Over 3 years (2021 to 2024), Halozyme Therapeutics's EBIT has grown at a 26.0% compound annual growth rate (CAGR), from $275.9M to $551.48M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.